Experimental obesity drug targets appetite through amylin, offering potential alternative to GLP-1 therapies

New probe presented astatine the yearly gathering of the European Association for the Study of Diabetes (EASD) successful Milan, Italy (Sept. 28–Oct. 2), and published successful The Lancet Diabetes & Endocrinology shows that play injections of the caller amylin-based obesity cause petrelintide tin alteration those treated to suffer much than 10% of their assemblage weight—generally little value nonaccomplishment than with existing incretin-based (GLP-1 RA) drugs, but besides with acold less broadside effects.